The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.

Authors: Haddad, Robert I., Adkins, Douglas, Licitra, Lisa F., Bruce, Justine Yang, Gillison, Maura L., Ahn, Myung-Ju, Hsieh, Ching-Yun, Wang, Hung-Ming, Psyrri, Amanda, Machiels, Jean-Pascal H., Balsara, Binaifer, Leoni, Mollie, Harrington, Kevin Joseph, Saba, Nabil F., Ho, Alan Loh

Source: Journal of clinical oncology. 39(15 suppl):TPS6087-TPS6087

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173209424.0x000001&indx=1&recIds=ETOCvdc_100173209424.0x000001

Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).

Authors: Sherman, Eric Jeffrey, Foster, Nathan R., Su, Yungpo Bernard, Shergill, Ardaman, Ho, Alan Loh, Konda, Bhavana, Ghossein, Ronald A, Ganly, Ian, Schwartz, Gary K.

Source: Journal of clinical oncology. 39(15 suppl):6076-6076

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173209305.0x000001&indx=1&recIds=ETOCvdc_100173209305.0x000001

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).

Authors: Burman, Bharat, Sherman, Eric Jeffrey, Dunn, Lara, Fetten, James Vincent, Michel, Loren S., Morris, Luc G.T., Ostrovnaya, Irina, Haque, Sofia, Pfister, David G., Ho, Alan Loh

Source: Journal of clinical oncology. 39(15 suppl):6002-6002

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173208512.0x000001&indx=1&recIds=ETOCvdc_100173208512.0x000001

First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.

Authors: Ho, Alan Loh, Posner, Marshall R., Niu, Jiaxin, Fu, Siqing, Leidner, Rom S., Pearson, Alexander T., Chung, Ki Y., Richardson, Debra L., Wang, Ding, Pimentel, Agustin, Nieva, Jorge J., Rosenberg, Ari, Burman, Bharat, Iacobucci, Corinne, Qing, Xiaoping, Hwang, Andy, Katchar, Kia, Schlienger, Katia, Matushansky, Igor, Pfister, David G.

Source: Journal of clinical oncology. 39(15 suppl):2502-2502

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173185325.0x000001&indx=1&recIds=ETOCvdc_100173185325.0x000001

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors: Ho, Alan Loh, Adkins, Douglas, Lorch, Jochen H., Thomas, Jacob Stephen, Grewal, Jaspreet Singh

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS6107-TPS6107, 1p

A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.

Authors: Abdelhamid Ahmed, Amr Hesham, Russell, Marika D., Kyriazidis, Natalia, Silver Karcioglu, Amanda, Sherman, Eric Jeffrey, Ho, Alan Loh, Fagin, James A, Wong, Richard J., Busaidy, Naifa Lamki, Zafereo, Mark E., Sadow, Peter, Park, Jong Chul, Wirth, Lori J., Randolph, Gregory W.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS6105-TPS6105, 1p

A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.

Authors: Mohamadpour, Maliheh, Sherman, Eric Jeffrey, Kriplani, Anuja, Fetten, James Vincent, Dunn, Lara, Michel, Loren S., Hung, Kin Wai, Baxi, Shrujal S., McDonald, Erin, Conybeare, Rachel, Katabi, Nora, Ostrovnaya, Irina, Pfister, David G., Ho, Alan Loh

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6048-6048, 1p

Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

Authors: Kang, Hyunseok, Ahn, Myung-Ju, Keam, Bhumsuk, Bowles, Daniel W., Wong, Deborah J.L., Ho, Alan Loh, Kim, Sung-Bae, Worden, Francis P., Yun, Tak, Jang, Seong, Meng, Xianzhang, Hanna, Glenn J.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6040-6040, 1p

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.

Authors: Desilets, Antoine, Pfister, David G., Wong, Winston, Sherman, Eric Jeffrey, Fetten, James Vincent, Hung, Kin Wai, Dunn, Lara, Ho, Alan Loh, Michel, Loren S.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6025-6025, 1p

Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).

Authors: Wong, Winston, Cracchiolo, Jennifer R., Riaz, Nadeem, Ganly, Ian, Sherman, Eric Jeffrey, Ho, Alan Loh, Morris, Luc, Ghossein, Ronald A, Haque, Sofia, Hung, Kin Wai, Kriplani, Anuja, Cohen, Marc, Boyle, Jay, McBride, Sean Matthew, Gelbum, Daphna Y., Michel, Loren S., Lee, Nancy Y., Wong, Richard J., Pfister, David G., Dunn, Lara

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6019-6019, 1p

Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

Authors: Liu, Dazhi, Makker, Vicky, Buonocore, Darren J., Shen, Ronglai, Yaeger, Rona, Ginsberg, Michelle S., Yeh, Randy, Johnson, Amanda, Offin, Michael, Solit, David B., Drilon, Alexander E., Rudin, Charles M., Kris, Mark G., Reis-Filho, Jorge S., Razavi, Pedram, Chandarlapaty, Sarat, Arora, Kanika, Berger, Michael F., Ho, Alan Loh, Li, Bob T.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p3025-3025, 1p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.